The safety of monosodium glutamates (MSG's) usage has generated much controversy locally and globally. This study investigates the efficacy of Loranthus micranthus in modulating the metabolic disorder associated with MSG intake. Thirty five (35) female rats randomized to three groups labeled 1 (7 rats), 2 (21 rats) and 3 (7 rats), respectively were used. They were administered with normal saline, MSG (200 mg/Kg) and MSG (200 mg/kg) + L. micranthus (600 mg/Kg), respectively for 28 days. Seven rats were then sacrificed from each group. The remaining rats in group 2 were then redistributed to groups labeled 4 and 5 consisting of 7 rats each. MSG was then withdrawn from all the rats. Group 4 was treated with L. Micranthus (600 mg/Kg) while normal saline was administered to group 5. All administrations were carried out for 30 days. The rats were then sacrificed and the serum was used for analysis. Analysis showed increase total cholesterol, triglyceride, low-density lipoprotein (LDL) -cholesterol, glucose and total protein concentrations and a reduced high-density lipoprotein (HDL) -cholesterol (when MSG was administered). These parameters were restored to normal with L. micranthus treatment. Although no histological change was observed in the uterus, there was a significant increase in organs relative weight when rats were placed on MSG but this was reversed with L. micranthus. The study suggests the efficacy of L. micranthus in reversing cardiovascular disorder and its ability to prevent MSG induced fibroid in rat.
Keywords: Cardiovascular diseases, cholesterol, Lipid profile, Loranthus micranthus, of monosodium glutamates (MSG).
African Journal of Biotechnology, Vol 13(39) 3989-3998